Literature DB >> 25170996

Blockade of the monocyte chemoattractant protein-1 receptor pathway ameliorates myocardial injury in animal models of ischemia and reperfusion.

Fadhil G Al-Amran1, Mandel Z Manson, Tennent K Hanley, Douglas L Hainz.   

Abstract

BACKGROUND: Myocardial infarction is accompanied by inflammatory responses that lead to the recruitment of leukocytes and subsequent myocardial damage and healing. Monocyte chemoattractant protein-1 (MCP-1, also known as CC chemokine ligand 2) and its receptor CC chemokine receptor 2 play a central role in the inflammatory response and myocardial injury after ischemia/reperfusion (I/R).
METHODS: Male adult C57BL/6 mice were anesthetized, and the left anterior descending coronary artery was ligated for 30 min. After reperfusion for 3 days, the ischemia and infarct sizes were determined.
RESULTS: The treatment of C57BL/6 mice with anti-MCP-1 reduced the infarct size and lessened myocardial inflammation. Furthermore, anti-MCP-1 prevented I/R-induced caspase-3/7 and -8 activities and reduced apoptosis. The treatment of operated mice with anti-MCP-1 shortly before the induction of myocardial ischemia resulted in a reversal of the infarction and improvements in histologic parameters.
CONCLUSION: These findings demonstrate a pathogenic role for MCP-1 in animal models of I/R and support the consideration of MCP-1 as a therapeutic target in myocardial ischemia.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25170996     DOI: 10.1159/000363657

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  3 in total

Review 1.  Chemokines in Myocardial Infarction.

Authors:  Bijun Chen; Nikolaos G Frangogiannis
Journal:  J Cardiovasc Transl Res       Date:  2020-05-15       Impact factor: 4.132

2.  Significant association between admission serum monocyte chemoattractant protein-1 and early changes in myocardial function in patients with first ST-segment elevation myocardial infarction after primary percutaneous coronary intervention.

Authors:  Yong Zhu; Chengping Hu; Yu Du; Jianwei Zhang; Jinxing Liu; Hongya Han; Yingxin Zhao
Journal:  BMC Cardiovasc Disord       Date:  2019-05-10       Impact factor: 2.298

3.  Dimethylfumarate protects against TNF-α-induced secretion of inflammatory cytokines in human endothelial cells.

Authors:  Simon Gerhardt; Veronika König; Monika Doll; Tsige Hailemariam-Jahn; Igor Hrgovic; Nadja Zöller; Roland Kaufmann; Stefan Kippenberger; Markus Meissner
Journal:  J Inflamm (Lond)       Date:  2015-08-06       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.